Biotech Team Develops ELISA Protocol for COVID-19 IgG Antibody Detection
Budapest, HU – 6 January 2021 – Life Science Newswire – ZTA Biotech, a Budapest-based biotech startup has announced the breakthrough development of a COVID-19 antibody (IgG) test using the ELISA protocol. This new detection method represents a great step forward in determining if patients have had COVID-19 and if they might still have immunity to the disease. Early results have proven 100% in specificity after testing 280 samples, and 100% sensitivity by testing 260 samples of recovered and symptomatic patients.
With a potential market of 5.8 billion people, who will likely need multiple antibody tests in the coming years, the formula has a massive potential across the globe. ZTA Biotech is currently offering the intellectual property rights to licensees and/or to a sole-rights purchaser, in order to help bring this breakthrough ELISA formula to market. Given the relatively small number of ELISA-based protocols when compared to the global demand, the sale offers a unique opportunity in combatting the Covid-19 pandemic, since it gives a greater detail into the prevalence of the disease. Also, brokering services of specialized companies are encouraged to facilitate an open and transparent dialogue between ZTA Biotech and potential clients.
The presented ELISA (Enzyme Linked Immunosorbent Assay) protocol is designed for the intended use in the post-vaccination period that is soon to commence (first/second trimester of 2021). Its microplates are coated with critical antigens which are the prime targets of the current vaccine developments (of any kind). The kit can also be used to monitor past, natural exposure to SARS-CoV-2 and to evaluate the possibility of re- infection.
The test is based on selective detection of human IgG antibodies that bind to SARS- CoV-2 antigens coated on the wells of the microplate and can be used for qualitative and semi-quantitative determination of human IgG. After the completion of the first critical reaction step, all unbound serum components are fully washed away and a series of reactions occur that will lead to a photometrically measurable step where the intensity of the obtained color is proportional to the quantity of SARS-CoV-2 IgG antibodies in the original sample. The whole process is fast, takes less than 2 hours to complete and can be fully automated. Also, it can be easily converted to a quantitative test, if needed.
The test was independently validated, with a sensitivity of 100% and a specificity of 100%, and compared to an approved test of a major test producer, the latter being outperformed. All testing for validation was carried out on samples collected between September 2019 – June 2020. The antibody test showed extremely low background noise, technical data available upon request. All sensitivity evaluation data was based on PCR tested, positive SARS-CoV-2 patients, all symptomatic after getting infected. No cross-reactivity was observed to SARS- CoV-2 IgM. The kit is extremely stable, has a long shelf life and opened kits are usable up to 3 months at storing temperatures of 5°C.
Initial equipment and personnel costs are low and are proportional to the desired monthly production. Also, the test can be adapted to potential virus mutations, based on sequencing data.
About ZTA Biotech
ZTA Biotech is the Intellectual Rights holder of the protocol and is represented by a Hungarian scientist. The formula was developed by an international team of researchers including a Canadian, an Israeli, and a Dutch scholar. The main research direction is achieved by an in-house developed, highly specialized software package for simulation and modeling of critical protein-protein interactions. The results based on the prediction of the algorithm are analyzed and translated into commercial products.
For more information, visit http://ztabiotech.com/home/
Tel USA: +1-512-234-3335
Tel Europe: +36 30 508 6127